Genetic studies in acute lymphoblastic leukemia

Acta Paediatrica Taiwanica

Volumn 41, Issue 6, 2000, Pages 303-307

  Pui, C H ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Genetic abnormalities; Minimal residual leukemia; Pharmacogenetics; Philadelphia chromosome

Indexed keywords

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEMATOPOIETIC CELL; MINIMAL RESIDUAL DISEASE; PHARMACODYNAMICS; REVIEW; RISK ASSESSMENT;

CHILD; CHROMOSOME ABERRATIONS; EPIDEMIOLOGY, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; PHARMACOGENETICS; PHILADELPHIA CHROMOSOME; PROGNOSIS;

EID: 0034534097     PISSN: 00016578     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Childhood leukemias: Current status and future perspective
2. Acute lymphoblastic leukemia
3. Monoclonoal origin of concordant T-cell malignancy in identical twins
4. Fetal origins of the TEL-AM1 fusion gene in identical twins with leukemia
5. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero
6. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots
7. Prenatal origin of acute lymphoblastic leukaemia in children
8. Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse types of early childhood acute lymphoblastic leukemia
9. Detection of clonotypic IGH and TCR rearrangements in the neonatal blood spots of infants and children with B-cell precursor acute lymphoblastic leukemia
10. Molecular genetics, natural history and the demise of childhood leukaemia
11. Biology and treatement of infant leukemias
12. Topoisomerase II inhibitor-related acute myeloid leukaemia
13. MLL rearrangements in haematological malignancies: Lessons from clinical and biological studies
14. Biological and therapeutic aspects of infant leukemia
15. A lack of function NAD(P) H: Quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions
16. Free radical formation by antitumor quinones
17. Topoisomerase inhibition by phenolic metabolites: A potential mechanism for benzene's clastogenic effects
18. Induction of topoisomerase -II mediated DNA cleavage by beta-lapachone and related naphthoquinones
19. Parental exposure and susceptibility factors in the etiology of infant leukemia
20. Acute lymphoblastic leukemia
21. Long term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric oncology group studies from 1986-1994
22. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes)
23. Children's Cancer Group trials in childhood acute lymphoblastic -Leukemia: 1983-1995
24. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts
25. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
26. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
27. Clinical characteristics and treatment outcome of Childhood acute lymphoblastic leukemia with the t (4;11) (q21;q23): A collaborative study of 40 cases
28. Hematologic malignancies with t (4;11) (q21;q23): a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases
29. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t (11;19) (q23; p13.3) translocation
30. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
31. New definition of remission in childhood acute lymphoblastic leukemia
32. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
33. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
34. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
35. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia
36. Sequential monitoring of minimal residual disease in childhood acute lymphoblastic leukemia
37. Acute lymphoblastic leukemia in children
38. Pharmacogenomics: Translating functional genomics into rational therapeutics
39. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyttransferase gene locus
40. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
41. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Relation to thiopurine metabolism
42. High incidence of secondary brain tumours after radiotherapy and antimetabolites
43. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans
44. Adverse effect of anticonvulsants on the efficacy of chemotherapy for acute lymphoblastic leukemia
45. Association of CYP3A4 genotype with treatment-related leukemia
46. Prevalence of the inactivating 609C(T polymorphism in the NAD(P)H: Quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
47. Gluthathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies
48. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms
49. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults
50. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
51. Identification of novel leukemia markers by comparative analysis of gene expression with DNA microarrays
52. In vivo eradication of human BCR/ABL-positive leukemia cells with a ABL kinaseinhibitor
53. Cytotoxic T celt response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia
54. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias including chronic myelogenous leukemia in blast crisis